Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology

被引:168
作者
Brown, Rikki A. M. [1 ,2 ,3 ]
Richardson, Kirsty L. [1 ,2 ]
Kabir, Tasnuva D. [1 ,2 ]
Trinder, Debbie [1 ,2 ,3 ]
Ganss, Ruth [1 ,2 ]
Leedman, Peter J. [1 ,2 ,3 ]
机构
[1] Queen Elizabeth II Med Ctr, Harry Perkins Inst Med Res, Perth, WA, Australia
[2] Univ Western Australia, UWA Ctr Med Res, Perth, WA, Australia
[3] Univ Western Australia, UWA Med Sch, Perth, WA, Australia
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
iron metabolism; cancer biology; metastasis; microRNAs; iron chelator; ferroptosis; tumor microenvironment; drug resistance; TRANSFERRIN RECEPTOR 1; EPITHELIAL-MESENCHYMAL TRANSITION; GELATINASE-ASSOCIATED LIPOCALIN; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; NEGATIVE BREAST-CANCER; SERUM FERRITIN LEVEL; PHASE-II TRIAL; IN-VITRO; HEPATOCELLULAR-CARCINOMA;
D O I
10.3389/fonc.2020.00476
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Iron is an essential nutrient that plays a complex role in cancer biology. Iron metabolism must be tightly controlled within cells. Whilst fundamental to many cellular processes and required for cell survival, excess labile iron is toxic to cells. Increased iron metabolism is associated with malignant transformation, cancer progression, drug resistance and immune evasion. Depleting intracellular iron stores, either with the use of iron chelating agents or mimicking endogenous regulation mechanisms, such as microRNAs, present attractive therapeutic opportunities, some of which are currently under clinical investigation. Alternatively, iron overload can result in a form of regulated cell death, ferroptosis, which can be activated in cancer cells presenting an alternative anti-cancer strategy. This review focuses on alterations in iron metabolism that enable cancer cells to meet metabolic demands required during different stages of tumorigenesis in relation to metastasis and immune response. The strength of current evidence is considered, gaps in knowledge are highlighted and controversies relating to the role of iron and therapeutic targeting potential are discussed. The key question we address within this review is whether iron modulation represents a useful approach for treating metastatic disease and whether it could be employed in combination with existing targeted drugs and immune-based therapies to enhance their efficacy.
引用
收藏
页数:25
相关论文
共 260 条
  • [31] CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer
    Cheng, Zhenguo
    Zhang, Danhua
    Gong, Baocheng
    Wang, Pengliang
    Liu, Funan
    [J]. ONCOTARGET, 2017, 8 (50) : 87244 - 87262
  • [32] Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer
    Cho, HanByoul
    Kim, Jae-Hoon
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2009, 57 (05) : 513 - 521
  • [33] Higher concentrations of serum iron and transferrin saturation but not serum ferritin are associated with cancer outcomes
    Chua, Anita C. G.
    Knuiman, Matthew W.
    Trinder, Debbie
    Divitini, Mark L.
    Olynyk, John K.
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2016, 104 (03) : 736 - 742
  • [34] Regulatory effects of ferritin on angiogenesis
    Coffman, Lan G.
    Parsonage, Derek
    D'Agostino, Ralph, Jr.
    Torti, Frank M.
    Torti, Suzy V.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (02) : 570 - 575
  • [35] Neither miR-7-5p nor miR-141-3p is a major mediator of iron-responsive transferrin receptor-1 mRNA degradation
    Corral, Victor M.
    Schultz, Eric R.
    Connell, Gregory J.
    [J]. RNA, 2019, 25 (11) : 1407 - 1415
  • [36] The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells
    Cragg, L
    Hebbel, RP
    Miller, W
    Solovey, A
    Selby, S
    Enright, H
    [J]. BLOOD, 1998, 92 (02) : 632 - 638
  • [37] The Role of Iron Regulation in Immunometabolism and Immune-Related Disease
    Cronin, Shane J. F.
    Woolf, Clifford J.
    Weiss, Guenter
    Penninger, Josef M.
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2019, 6
  • [38] Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway
    Cui, Can
    Cheng, Xiaojing
    Yan, Liang
    Ding, Huirong
    Guan, Xiaoya
    Zhang, Wenlong
    Tian, Xiuyun
    Hao, Chunyi
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6323 - 6341
  • [39] The transferrin receptor and the targeted delivery of therapeutic agents against cancer
    Daniels, Tracy R.
    Bernabeu, Ezequiel
    Rodriguez, Jose A.
    Patel, Shabnum
    Kozman, Maggie
    Chiappetta, Diego A.
    Holler, Eggehard
    Ljubimova, Julia Y.
    Helguera, Gustavo
    Penichet, Manuel L.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2012, 1820 (03): : 291 - 317
  • [40] Transferrin receptor 1: a target for antibody-mediated cancer therapy
    Daniels-Wells, Tracy R.
    Penichet, Manuel L.
    [J]. IMMUNOTHERAPY, 2016, 8 (09) : 991 - 994